epidiolex
epidiolex: developed by 2 companies · 8 clinical trials tracked.
epidiolex evidence translation
What we can confirm
8 tracked trials
What it means
What to watch
Prepared research question
What is verified about epidiolex, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence7 indications · 1 study sponsors
Related indications
Study sponsors
Development Pipeline (2)
| Company | Phase |
|---|---|
| GW PHARMACEUTICALS PLC (GWPH) | Phase 3 |
| Jazz Pharmaceuticals plc (JAZZ) Seizures; Lennox Gastaut Syndrome; Maternal Complications | Approved |
Clinical Trials (8)
Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial
Primary endpoint: Retention in OUD Treatment
Epidiolex Pilot Trial for Presymptomatic Treatment of Sturge-Weber Syndrome
Primary endpoint: Safe completion as assessed by the number of participants with no significant side effects
A Clinical Study of the Transition of Children From 'Artisanal' Cannabidiol to Epidiolex
Primary endpoint: The success rate of transition of children from 'artisanal' CBD to Epidiolex.
Randomized, Double-Blind, Placebo-Controlled Cross-Over Study to Evaluate the Effects of Cannabidiol on Neurobehavioral and Function Outcomes in Sanfilippo Syndrome
Primary endpoint: Sanfilippo Behavior Rating Scale (SBRS)- mood/anger/aggression score
Observational Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy to Assess the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant
Primary endpoint: Rate of MCM
Observational, Prospective, Multicenter Study of Epidyolex® (Cannabidiol CBD 100 mg/ml) Oral Solution, as Adjunctive Treatment for Seizures Associated With Lennox- Gastaut Syndrome (LGS), Dravet Syndrome (DS) and Tuberous Sclerosis Complex (TSC)
Primary endpoint: Number of Participants Remaining on Therapy from Enrollment
Long-term Follow-up of a Multicentre, Non-interventional, Prospective Cohort of Participants Prescribed Epidyolex in France in a Real-life Setting
Primary endpoint: Retention Rate Percentage After Initiation of Treatment With Epidyolex
Efficacy of Epidiolex in Patients With Electrical Status Epilepticus of Sleep (ESES).
Primary endpoint: Frequency of Spike Wave Index
Frequently asked questions
Who is developing epidiolex?
epidiolex is being developed by GW PHARMACEUTICALS PLC, Jazz Pharmaceuticals plc.
How many clinical trials involve epidiolex?
BioSniper tracks 8 clinical trials involving epidiolex.